Cover image of the article: Paraoxonase and Arylesterase activities of human serum paraoxonase in coronary artery disease

Image Credit:Koomesh

Paraoxonase and Arylesterase activities of human serum paraoxonase in coronary artery disease

Authors

Abdolkarim Mahrooz,*, Mohammad Nori, MohammadReza Rashidi, Naser AslanAbadi, Dardi Ghojegh, Atefeh Azari
*Corresponding Author: Email: kmahrooz@yahoo.com

Koomesh:Vol. 10, issue 1; 1-6
Published online:Oct 24, 2008
Article type:Research Article
How to Cite:Mahrooz A, Nori M, Rashidi M, AslanAbadi N, Ghojegh D, et al. Paraoxonase and Arylesterase activities of human serum paraoxonase in coronary artery disease. koomesh. 2008;10(1):e152212. doi:

Abstract

Introduction: Considering the importance of serum paraoxonase (PON1) in preventing from production of oxidized low-density lipoprotein (LDL), and consequently, its role in prohibiting from development of atherosclerosis, we investigated paraoxonase and arylesterase activities of PON1 in patients with coronary artery disease (CAD) and with different coronary stenosis. Materials and Methods: In the present study, 120 patients with CAD were examined and their stenosis documented by coronary angiography. Then, the patients were divided into two groups: 60 patients with less than 50% of stenosis and 60 patients with more than 70% of stenosis. Paraoxonase and arylesterase activity was measured with substrates of paraoxon and phenylacetate, respectively. The effects of eight drugs, which are prescribed in cardiovascular diseases, were assayed on paraoxonase activity. Results: There were no significant differences in LDL-C, total cholesterol and triglyceride levels between two groups, but HDL levels in patients with >70% of stenosis were significantly decreased as compared with those of patients who had

Highlights

Copyright

© 2008, Author(s). This open-access article is available under the Creative Commons Attribution 4.0 (CC BY 4.0) International License (https://creativecommons.org/licenses/by/4.0/), which allows for unrestricted use, distribution, and reproduction in any medium, provided that the original work is properly cited.

Similar Articles

25
Mar
2011
Determination of serum paraoxonase phenotype distribution by double-substrate method in patients with coronary artery disease

Determination of serum paraoxonase phenotype distribution by double-substrate method in patients with coronary artery disease

Abdolkarim Mahrooz,
Mohammad Nori,
Mohammad-Reza Rashidi,
Naser AslanAbadi,
Durdi Ghojagh

Mahrooz A, Nori M, Rashidi M, AslanAbadi N, Ghojagh D. Determination of serum paraoxonase phenotype distribution by double-substrate method in patients with coronary artery disease. koomesh. 2011;12(3):e152455. doi:

1
Dec
2017
Association Assessment of Paraoxonase 1 Gene Polymorphism with Coronary Artery Disease in Golestan, Iran

Association Assessment of Paraoxonase 1 Gene Polymorphism with Coronary Artery Disease in Golestan, Iran

Samaneh Abdolahpour,
Azam Bakhshandeh,
Touraj Farazmandfar,
Mehdi Rayatnavaz,
Majid Shahbazi

Abdolahpour S, Bakhshandeh A, Farazmandfar T, Rayatnavaz M, Shahbazi M. Association Assessment of Paraoxonase 1 Gene Polymorphism with Coronary Artery Disease in Golestan, Iran. Int Cardiovasc Res J. 2017;11(4):e61212. doi:

31
Mar
2014
The Correlation between Serum ApoA1 and B and Coronary Artery Disease as Well as Its Severity

The Correlation between Serum ApoA1 and B and Coronary Artery Disease as Well as Its Severity

SeverityNavid Reza Mashayekhi,
Saeid Sadrnia,
Ali Chehrei,
Javad Javaheri

Mashayekhi SR, Sadrnia S, Chehrei A, Javaheri J. The Correlation between Serum ApoA1 and B and Coronary Artery Disease as Well as Its Severity. Int Cardiovasc Res J. 2017;8(1):e12043. doi:

30
May
2021
Investigation of Antioxidant Status in Coronary Artery Disease Patients

Investigation of Antioxidant Status in Coronary Artery Disease Patients

Negar Dinarvand,
Mehdi Rasouli,
Fatemeh Meshkini,
Mehryar Zargari

Dinarvand N, Rasouli M, Meshkini F, Zargari M. Investigation of Antioxidant Status in Coronary Artery Disease Patients. J Adv Immunopharmacol. 2021;1(1):e115238. doi: https://doi.org/10.5812/tms.115238

15
Sep
2016
The Association between PAI-1 Gene Promoter Polymorphism and Serum Serpin E1, MDA, and Hs-CRP Levels in Coronary Artery Disease

The Association between PAI-1 Gene Promoter Polymorphism and Serum Serpin E1, MDA, and Hs-CRP Levels in Coronary Artery Disease

Ansar Karimian,
Safar Farajnia,
Morteza Ghojazadeh,
Fatemeh Khaki-Khatibi

Karimian A, Farajnia S, Ghojazadeh M, Khaki-Khatibi F. The Association between PAI-1 Gene Promoter Polymorphism and Serum Serpin E1, MDA, and Hs-CRP Levels in Coronary Artery Disease. Int Cardiovasc Res J. 2016;10(3):e10176. doi:

More by these authors

Abdolkarim MahroozPubMedScholar
Mohammad NoriPubMedScholar
MohammadReza RashidiPubMedScholar
Naser AslanAbadiPubMedScholar
Dardi GhojeghPubMedScholar
Atefeh AzariPubMedScholar
Share
Cited by
Metrics